PTPN11 and neoplasm: Systemic SHP2 inhibition in mice bearing tumor types selected for SHP2‐independent tumor cell growth promotes degeneration of the tumor vasculature and blood extravasation; reduces tumor vascularity and blood perfusion; and increases tumor necrosis.